Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

v3.23.2
Stock-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of Stock Option Activities
Following is a summary of stock option activities for the six months ended June 30, 2023:
Options Weighted
Average
Exercise Price
Weighted
Average
Grant Date
Fair Value
Weighted
Average
Remaining
Life
(years)
Intrinsic
Value
Outstanding – January 1, 2023 7,603,864  $ 0.19  $ 0.21  4.6 $ 25,795 
Granted —  —  — 
Exercised (300,785) 0.18  0.24 
Forfeited —  —  — 
Outstanding – June 30, 2023
 7,303,079  $ 0.19  $ 0.21  4.1 $ 27,402 
Exercisable as of June 30, 2023
 7,303,079  $ 0.19  $ 0.21  4.1 $ 27,402 
Summary of Restricted Stock Activity

Restricted Stock Units
Weighted Average Grant Date
Fair Value
Non-vested – January 1, 2023 7,466,636  $ 5.52 
Granted
 275,235  3.11 
Vested
 (834,924) 6.61 
Forfeited
 (126,283) 5.77 
Non-vested – June 30, 2023
 6,780,664  $ 5.29 
Summary of Stock-based Compensation Expense
Stock-based compensation expense for stock options and restricted stock units in the unaudited interim condensed consolidated statements of operations is summarized as follows:
Three Months Ended June 30,
Six Months Ended June 30,
2023 2022 2023 2022
Software development
 $ 293  $ 254  $ 461  $ 529 
General and administrative(1)
 2,376  1,495  5,012  3,218 
Selling and marketing
 128  95 206  195
Total stock-based compensation expense
 $ 2,797  $ 1,844  $ 5,679  $ 3,942 
________
(1) For the six months ended June 30, 2023, the Company included a credit of $339 in connection with the settlement of the equity-based portion of contingent consideration related to the acquisition of Trinity Air Medical, Inc. that was paid in the first quarter of 2023 in respect of 2022 results.